Urinary Metabolites in Leukaemic Patients During Treatment
Author Information
Author(s): J. Gerbrandy, H. B. A. Hellendoorn, H. Lokkerbol
Primary Institution: Antoni van Leeuwenhoek-Huis, Netherlands Cancer Institute, Amsterdam
Hypothesis
The urinary excretion of metabolites will increase during the destruction of tumour tissue in leukaemic patients receiving radiological treatment.
Conclusion
The excess excretion of urinary phosphate serves as a rough quantitative measure of tumour loss in leukaemic patients undergoing treatment.
Supporting Evidence
- The rise of urinary excretion of metabolites was closely related to the loss of tumour tissue during treatment.
- Excess excretion of phosphate correlated with the estimated loss of leukaemic cells.
- Patients with no measurable decrease in tumour tissue did not show a rise in metabolite excretion.
Takeaway
When leukaemic patients are treated with radiation, their bodies release more waste products from the dying cancer cells, which can help doctors understand how much cancer is being destroyed.
Methodology
The study measured urinary excretion of metabolites in 5 leukaemic and 3 cancer patients on a standardized diet during X-ray treatment.
Limitations
The study had a small sample size and only included specific types of leukaemia and cancer patients.
Participant Demographics
Included 5 leukaemic patients (2 with chronic myeloid leukaemia and 3 with chronic lymphoid leukaemia) and 3 cancer patients (2 with metastasized carcinoma and 1 with reticulosarcoma).
Want to read the original?
Access the complete publication on the publisher's website